The small bright red cobblestone texture of healthy granulation tissue is just that: a granule of new collagen and the new growth of capillaries. Hypergranulation (Figure 1) is the excessive growth of granulation tissue, a symptom of a dysfunctional wound environment. Providers can identify hypergranulation by its appearance. As opposed to the bright, bubbly red appearance of healthy granulation tissue, unhealthy granulation, and hypergranulation tissue can present as large lobes of red tissue, and the coloration can vary between bright red and darker shades. These lobes will typically sit above skin level.
Figure 1: A. Hypergranulation to right lateral foot due to biofilm. B. Hypergranulation 1 week following of sharp debridement and rigorous wound hygiene. C. Resolution of hypergranulation at week 4 following continued sharp debridement, silver nitrate application, and rigorous wound hygiene.
This growth may be due to extrinsic factors, like excessive bacterial load and moisture, or intrinsic factors that can also contribute to excess inflammation and nutritional deficiencies.1
Hypergranulation tissue tends to be friable, meaning it easily bleeds. When located next to a stoma, the serous and sanguineous drainage from hypergranulation tissue can contribute to poor pouch adherence and, ultimately, issues with leaking ostomy appliances. In hard-to-heal wounds, hypergranulation tissue can proliferate over the wound's edges, leading to early epithelial edge contact inhibition. This condition prevents further edge migration and can stagnate or completely stall wound healing. Addressing hypergranulation tissue should be coupled with managing any instigating factors: Excess moisture can be addressed with a more absorbent dressing, and inhibitory bacterial loads can be tampered down with non-cytotoxic antimicrobials. Several options address this over-proliferation of tissue, including debridement and some dressings.
Sharp, mechanical, and chemical debridement are all methods that can address hypergranulation. Each debridement method can be painful for patients if the hypergranulaton tissue is in a sensitive area. Patients are typically pre-medicated with a topical anesthetic such as lidocaine prior to debridement to address pain and allow for thorough debridement.
The application of a topical corticosteroid is another treatment option for hypergranulation tissue. Applying 0.1%-0.5% triamcinolone cream 2-3 times per day or triamcinolone ointment with less frequency can effectively treat hypergranulation tissue without the pain and stress associated with debridement.3 This method can be especially valuable in the pediatric population.4 Once the hypergranulation tissue is resolved, the steroid ointment should be stopped as atrophy and delayed wound healing can occur with continued use (Figure 2).
Figure 2: A. Left anterior foot after serial treatment with triamcinolone ointment. B. Left anterior foot 1 month following cessation of triamcinolone ointment. Note cobble-stoning of granulation tissue, and bright red healthy coloration.
Polyvinyl alcohol dressings (PVA) with antimicrobial pigments have been found to treat some cases of hypergranulation.1 Providers can use this method of hypergranulation topical treatment in combination with a topical corticosteroid. Using dressings as the sole treatment is most effective for mild hypergranulation. Large or deep lobes typically require additional treatment.
Hypergranulation tissue indicates a dysfunctional wound microenvironment, and it can lead to ostomy pouch leakage, delayed wound healing, or wound stagnation. Debridement, topical corticosteroid application, and PVA antimicrobial dressings are accessible treatment options. Due to the tendency for hypergranulation tissue to reform, serial treatments are often necessary until wound closure or the resolution of the peristomal hypergranulation.
About the Author
Laura Swoboda, DNP, APNP, FNP-BC, CWOCN-AP, is a Professor of Translational Science, Nurse Practitioner, and Wound Healing Coordinator at Froedtert & the Medical College of Wisconsin, where they advocate for nurse practitioners and nurse participation in research. They completed their Doctor of Nursing Practice degree at University of Wisconsin Milwaukee (UWM). Dr. Swoboda is a faculty member of the Clinical & Translational Science Institute of Southeast Wisconsin where they serve as principal investigator for quality improvement, evidence based practice, and research projects including the planning, implementation, management, and dissemination of projects in chronic wound care. They further participate in the research process in serving as a peer reviewer for scientific journals. Dr. Swoboda is on the National Pressure Injury Advisory Panel’s Prophylactic Dressing Standards Initiative Task Force, a member of the editorial board for the Wound Care Learning Network and Wound Management and Prevention, and on the board of directors for the WOCNCB and the AAWC.
The views and opinions expressed in this content are solely those of the contributor, and do not represent the views of WoundSource, HMP Global, its affiliates, or subsidiary companies.